{"id":6872,"date":"2026-01-22T18:35:58","date_gmt":"2026-01-22T17:35:58","guid":{"rendered":"https:\/\/www.ffrdiabete.org\/?p=6872"},"modified":"2026-01-22T19:08:03","modified_gmt":"2026-01-22T18:08:03","slug":"type-2-diabetes-cure-or-remission-can-it-happen","status":"publish","type":"post","link":"https:\/\/www.ffrdiabete.org\/en\/type-2-diabetes-cure-or-remission-can-it-happen\/","title":{"rendered":"PR\u00caT1D: screening earlier, acting fairer regarding type 1 diabetes!"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text css=””]<\/p>\n

\"\"PR\u00caT1D – National project for the screening and management of presymptomatic type 1 diabetes, NEWLY SUPPORTED by the FFRD<\/strong><\/span><\/h3>\n
\n
<\/div>\n
Background<\/strong><\/span><\/div>\n
\n

The recently published French position statement by the SFD\/SFEDP<\/strong> provides an initial reference framework for the screening and management of preclinical type 1 diabetes (T1D) in relatives of individuals living with T1D. In addition, new ICD-10 diagnostic codes<\/strong> have been created for stage 1 (E10.A1) and stage 2 (E10.A2) T1D, suggesting that the management of preclinical T1D following screening is moving toward integration into routine clinical care <\/p>\n

The PR\u00caT1D <\/strong><\/em>study, promoted by the Fondation Francophone pour la Recherche sur le Diab\u00e8te (FFRD<\/strong> ), aims to remove 3 barriers<\/strong> to the development of this new patient pathway:<\/p>\n

 <\/p>\n

\n
1) Access to screening<\/strong><\/span><\/div>\n
\n

PR\u00caT1D<\/strong><\/em> proposes to simplify this step, which represents the largest volume of testing, and to move it outside hospitals and private practices<\/strong> by using capillary blood samples<\/strong> that can be self-collected at home<\/strong> and sent by mail to a centralized screening laboratory at Cochin Hospital. The four T1D-associated autoantibodies (IAA, GAD, IA-2, ZnT8) are measured there using a validated ADAP assay. Then, each screening result<\/strong> is communicated to the referring center<\/strong>, which informs the participant and organizes follow-up in accordance with the French position statement. An option for sample collection by healthcare professionals at participating centers is also available. <\/p>\n<\/div>\n<\/div>\n

 <\/p>\n

\n
\n

\"\"<\/p>\n

 <\/p>\n

2) Harmonized care treatment and management<\/strong><\/span><\/div>\n
\n

The creation of a harmonized follow-up and care pathway<\/strong> for relatives with a positive screening test. Bu the end, PR\u00caT1D<\/strong><\/em> is proposing to simplify the process, using a digital health platform<\/strong> developed with startup Ailin. This platform will include 3 modules: <\/p>\n